PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	22-26	interleukin 17A	Homo sapiens	97-103
33777147-13	2021	In terms of GMSC migration through the microperforated membrane, a homogeneous CD146 population migrates more statistically significant than a heterogeneous GMSC population.	gmsc	12-16	melanoma cell adhesion molecule	Homo sapiens	79-84
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	78-82	TNF receptor associated factor 6	Homo sapiens	204-209
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	22-26	interleukin 10	Homo sapiens	118-123
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	78-82	nuclear factor kappa B subunit 1	Homo sapiens	210-219
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	22-26	interleukin 17 receptor A	Homo sapiens	191-198
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	22-26	TRAF3 interacting protein 2	Homo sapiens	199-203
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	22-26	TNF receptor associated factor 6	Homo sapiens	204-209
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	22-26	nuclear factor kappa B subunit 1	Homo sapiens	210-219
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	78-82	interleukin 17A	Homo sapiens	97-103
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	78-82	interleukin 10	Homo sapiens	118-123
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	78-82	interleukin 17 receptor A	Homo sapiens	191-198
34953015-7	2022	The results show that GMSC-Exo has the same or stronger effects compared with GMSC in inhibiting IL-17A and promoting IL-10, reducing incidences and bone erosion of arthritis, via inhibiting IL-17RA-Act1-TRAF6-NF-kappaB signal pathway.	gmsc	78-82	TRAF3 interacting protein 2	Homo sapiens	199-203
35464198-10	2022	Furthermore, compared to treatment with LPS, treatment with GMSC-Exo attenuated the expression of NF-kappaB signaling and Wnt5a in LPS-induced PDLSCs.	gmsc	60-64	nuclear factor kappa B subunit 1	Homo sapiens	98-107
35464198-10	2022	Furthermore, compared to treatment with LPS, treatment with GMSC-Exo attenuated the expression of NF-kappaB signaling and Wnt5a in LPS-induced PDLSCs.	gmsc	60-64	Wnt family member 5A	Homo sapiens	122-127
35464198-11	2022	In conclusion, we confirmed that GMSC-Exo could suppress the inflammatory response of PDLSCs by regulating the expression of NF-kappaB signaling and Wnt5a, which paves the way for the establishment of a therapeutic approach for periodontitis.	gmsc	33-37	nuclear factor kappa B subunit 1	Homo sapiens	125-134
35464198-11	2022	In conclusion, we confirmed that GMSC-Exo could suppress the inflammatory response of PDLSCs by regulating the expression of NF-kappaB signaling and Wnt5a, which paves the way for the establishment of a therapeutic approach for periodontitis.	gmsc	33-37	Wnt family member 5A	Homo sapiens	149-154
33582592-9	2021	The GMSC-Exos group showed lower Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-1beta (IL-1beta), and cluster of differentiation 86 (CD86) expression levels than the high-lipid group, and the highest levels of Interleukin-10 (IL-10) among all groups.	gmsc	4-8	tumor necrosis factor	Homo sapiens	33-60
33582592-9	2021	The GMSC-Exos group showed lower Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-1beta (IL-1beta), and cluster of differentiation 86 (CD86) expression levels than the high-lipid group, and the highest levels of Interleukin-10 (IL-10) among all groups.	gmsc	4-8	interleukin 1 alpha	Homo sapiens	115-123
33582592-9	2021	The GMSC-Exos group showed lower Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-1beta (IL-1beta), and cluster of differentiation 86 (CD86) expression levels than the high-lipid group, and the highest levels of Interleukin-10 (IL-10) among all groups.	gmsc	4-8	tumor necrosis factor	Homo sapiens	62-71
33582592-9	2021	The GMSC-Exos group showed lower Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-1beta (IL-1beta), and cluster of differentiation 86 (CD86) expression levels than the high-lipid group, and the highest levels of Interleukin-10 (IL-10) among all groups.	gmsc	4-8	interleukin 6	Homo sapiens	74-87
33582592-9	2021	The GMSC-Exos group showed lower Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-1beta (IL-1beta), and cluster of differentiation 86 (CD86) expression levels than the high-lipid group, and the highest levels of Interleukin-10 (IL-10) among all groups.	gmsc	4-8	interleukin 10	Homo sapiens	238-252
33582592-9	2021	The GMSC-Exos group showed lower Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-1beta (IL-1beta), and cluster of differentiation 86 (CD86) expression levels than the high-lipid group, and the highest levels of Interleukin-10 (IL-10) among all groups.	gmsc	4-8	interleukin 10	Homo sapiens	254-259
33582592-9	2021	The GMSC-Exos group showed lower Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-1beta (IL-1beta), and cluster of differentiation 86 (CD86) expression levels than the high-lipid group, and the highest levels of Interleukin-10 (IL-10) among all groups.	gmsc	4-8	interleukin 6	Homo sapiens	89-93
33582592-10	2021	The GMSC-Exos group showed significant reductions in TNF-alpha levels than the high-lipid group, and significant escalations in IL-10 levels than the other two groups.	gmsc	4-8	tumor necrosis factor	Homo sapiens	53-62
33582592-9	2021	The GMSC-Exos group showed lower Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-1beta (IL-1beta), and cluster of differentiation 86 (CD86) expression levels than the high-lipid group, and the highest levels of Interleukin-10 (IL-10) among all groups.	gmsc	4-8	interleukin 1 beta	Homo sapiens	96-113
33582592-10	2021	The GMSC-Exos group showed significant reductions in TNF-alpha levels than the high-lipid group, and significant escalations in IL-10 levels than the other two groups.	gmsc	4-8	interleukin 10	Homo sapiens	128-133
30335555-6	2019	Meanwhile, we showed an elevated expression level of Shh-which is essential for development, homeostasis, and maintenance of the taste bud organ-in wounded areas of the tongue among animals treated with GMSC/SIS-ECM or exosome/SIS-ECM as compared with SIS-ECM control.	gmsc	203-207	sonic hedgehog signaling molecule	Homo sapiens	53-56
30311853-5	2019	Importantly, the findings suggest that GMSC-derived EVs promoted the expression of Schwann cell dedifferentiation/repair phenotype-related genes in vitro, particularly c-JUN, a key transcription factor that drives the activation of repair phenotype of Schwann cells during PNI and regeneration.	gmsc	39-43	jun proto-oncogene	Mus musculus	168-173
30311853-5	2019	Importantly, the findings suggest that GMSC-derived EVs promoted the expression of Schwann cell dedifferentiation/repair phenotype-related genes in vitro, particularly c-JUN, a key transcription factor that drives the activation of repair phenotype of Schwann cells during PNI and regeneration.	gmsc	39-43	5'-nucleotidase, cytosolic III	Mus musculus	273-276
31076346-6	2019	GMSC treatment also resulted in a dramatically decreased level of NF-kappaB p65/p50 in osteoclasts in vitro.	gmsc	0-4	RELA proto-oncogene, NF-kB subunit	Homo sapiens	76-79
31076346-6	2019	GMSC treatment also resulted in a dramatically decreased level of NF-kappaB p65/p50 in osteoclasts in vitro.	gmsc	0-4	nuclear factor kappa B subunit 1	Homo sapiens	80-83
31076346-7	2019	Infusion of GMSC to CIA significantly attenuated the severity of arthritis, pathology scores, frequency of osteoclasts, particularly bone erosion, as well as a decreased expression of RANKL in synovial tissues in vivo.	gmsc	12-16	nuclear receptor coactivator 5	Homo sapiens	20-23
31076346-7	2019	Infusion of GMSC to CIA significantly attenuated the severity of arthritis, pathology scores, frequency of osteoclasts, particularly bone erosion, as well as a decreased expression of RANKL in synovial tissues in vivo.	gmsc	12-16	TNF superfamily member 11	Homo sapiens	184-189
31076346-8	2019	Blockade of CD39/CD73 or adenosine receptors has significantly abrogated the suppressive ability of GMSC in vitro and therapeutic effect of GMSC on bone erosion during CIA in vivo.	gmsc	100-104	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	12-16
31076346-8	2019	Blockade of CD39/CD73 or adenosine receptors has significantly abrogated the suppressive ability of GMSC in vitro and therapeutic effect of GMSC on bone erosion during CIA in vivo.	gmsc	100-104	5'-nucleotidase ecto	Homo sapiens	17-21
31076346-8	2019	Blockade of CD39/CD73 or adenosine receptors has significantly abrogated the suppressive ability of GMSC in vitro and therapeutic effect of GMSC on bone erosion during CIA in vivo.	gmsc	140-144	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	12-16
31076346-8	2019	Blockade of CD39/CD73 or adenosine receptors has significantly abrogated the suppressive ability of GMSC in vitro and therapeutic effect of GMSC on bone erosion during CIA in vivo.	gmsc	140-144	5'-nucleotidase ecto	Homo sapiens	17-21
31076346-8	2019	Blockade of CD39/CD73 or adenosine receptors has significantly abrogated the suppressive ability of GMSC in vitro and therapeutic effect of GMSC on bone erosion during CIA in vivo.	gmsc	140-144	nuclear receptor coactivator 5	Homo sapiens	168-171
31076346-9	2019	INTERPRETATION: GMSC inhibit osteoclast formation in vitro and in vivo partially via CD39-CD73-adenosine signals.	gmsc	16-20	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	85-89
31076346-9	2019	INTERPRETATION: GMSC inhibit osteoclast formation in vitro and in vivo partially via CD39-CD73-adenosine signals.	gmsc	16-20	5'-nucleotidase ecto	Homo sapiens	90-94
33359765-6	2021	Local injection of GMSC-derived exosomes significantly reduced periodontal bone resorption and the number of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts, and these effects were further enhanced by preconditioning of GMSCs with TNF-alpha.	gmsc	19-23	tumor necrosis factor	Homo sapiens	247-256
33359765-9	2021	These results indicate that significant ability of the TNF-alpha-preconditioned GMSC-derived exosomes to regulate inflammation and osteoclastogenesis paves the way for establishment of a new therapeutic approach for periodontitis.	gmsc	80-84	tumor necrosis factor	Homo sapiens	55-64
32304668-6	2020	We further demonstrated that CD39 produced from GMSC exerted its osteogenic capacity through the Wnt/beta-catenin pathway.	gmsc	48-52	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	29-33
32304668-6	2020	We further demonstrated that CD39 produced from GMSC exerted its osteogenic capacity through the Wnt/beta-catenin pathway.	gmsc	48-52	catenin beta 1	Homo sapiens	101-113
30664802-6	2019	Phenotype analyses showed that the frequencies of NK1.1+ and CD11b+ cells, as well as CD4 T cells in the spleen, were suppressed in GMSC-treated mice compared with the PBS- or fibroblast-treated control groups.	gmsc	132-136	integrin subunit alpha M	Homo sapiens	61-66
30664802-7	2019	Additionally, GMSC treatment markedly increased the numbers of interleukin (IL)-10+ regulatory T cells, reduced the secretion of pro-inflammatory cytokines, and increased production of anti-inflammatory cytokines.	gmsc	14-18	interleukin 10	Homo sapiens	63-82
30622237-4	2019	Furthermore, GMSC-mediated prevention of acute GVHD was dependent on CD39 signaling that play an important role in the function and stability of Tregs.	gmsc	13-17	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	69-73
28340277-8	2017	The GMSC also showed higher expression of IL-10 24 h after injury, GDNF at 48 h and 8 days, and VEGF at 21 days.	gmsc	4-8	interleukin 10	Rattus norvegicus	42-47
29751776-9	2018	RESULTS: TNF-alpha differently affected GMSC proliferation and the expression of inflammatory-related proteins (interleukin (IL)-6, IL-10, transforming growth factor (TGF)-beta, and cyclooxygenase (COX)-2) dependent on its concentration.	gmsc	40-44	tumor necrosis factor	Homo sapiens	9-18
29751776-10	2018	A high TNF-alpha concentration decreased the GMSC viability and impaired the positive cross-talk between GMSCs and endothelial cells, probably by enhancing the amount of pro-inflammatory cytokines in the GMSC secretome.	gmsc	45-49	tumor necrosis factor	Homo sapiens	7-16
29751776-10	2018	A high TNF-alpha concentration decreased the GMSC viability and impaired the positive cross-talk between GMSCs and endothelial cells, probably by enhancing the amount of pro-inflammatory cytokines in the GMSC secretome.	gmsc	105-109	tumor necrosis factor	Homo sapiens	7-16
28340277-8	2017	The GMSC also showed higher expression of IL-10 24 h after injury, GDNF at 48 h and 8 days, and VEGF at 21 days.	gmsc	4-8	vascular endothelial growth factor A	Rattus norvegicus	96-100
28340277-8	2017	The GMSC also showed higher expression of IL-10 24 h after injury, GDNF at 48 h and 8 days, and VEGF at 21 days.	gmsc	4-8	glial cell derived neurotrophic factor	Rattus norvegicus	67-71
27836015-8	2016	CONCLUSIONS: GMSC-based therapy induces T-cell apoptosis via the FasL/Fas pathway and results in immune tolerance and amelioration of the CIA inflammation.	gmsc	13-17	Fas ligand (TNF superfamily, member 6)	Mus musculus	65-69
27484807-8	2016	Moreover, GMSC administration promoted the expression of EP3, a prostaglandin E receptor, and the application of sulprostone, an agonist of EP3, significantly attenuated CHS to a similar degree as that of GMSC administration.	gmsc	10-14	prostaglandin E receptor 3 (subtype EP3)	Mus musculus	57-60
21987520-6	2011	Mechanistically, GMSC-induced blockage of de novo synthesis of proinflammatory cytokines by MCs is mediated partly by the tumor necrosis factor-alpha/prostaglandin E(2) (PGE(2)) feedback axis.	gmsc	17-21	tumor necrosis factor	Homo sapiens	122-149
20734355-6	2010	Mechanistically, GMSC treatment mitigated local inflammation mediated by a suppressed infiltration of inflammatory cells and production of IL-6 and TNF-alpha, and an increased expression of IL-10.	gmsc	17-21	interleukin 6	Homo sapiens	139-143
20734355-6	2010	Mechanistically, GMSC treatment mitigated local inflammation mediated by a suppressed infiltration of inflammatory cells and production of IL-6 and TNF-alpha, and an increased expression of IL-10.	gmsc	17-21	tumor necrosis factor	Homo sapiens	148-157
20734355-6	2010	Mechanistically, GMSC treatment mitigated local inflammation mediated by a suppressed infiltration of inflammatory cells and production of IL-6 and TNF-alpha, and an increased expression of IL-10.	gmsc	17-21	interleukin 10	Homo sapiens	190-195
20734355-7	2010	The GMSC-induced suppression of TNF-alpha secretion by macrophages appears to correlate with impaired activation of NFkappaB p50.	gmsc	4-8	tumor necrosis factor	Homo sapiens	32-41
20734355-7	2010	The GMSC-induced suppression of TNF-alpha secretion by macrophages appears to correlate with impaired activation of NFkappaB p50.	gmsc	4-8	CD40 molecule	Homo sapiens	125-128